Immunome Inc (IMNM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immunome Inc stock (IMNM) is currently trading at $20.30. Immunome Inc PS ratio (Price-to-Sales) is 329.41. Analyst consensus price target for IMNM is $35.54. WallStSmart rates IMNM as Sell.
- IMNM PE ratio analysis and historical PE chart
- IMNM PS ratio (Price-to-Sales) history and trend
- IMNM intrinsic value — DCF, Graham Number, EPV models
- IMNM stock price prediction 2025 2026 2027 2028 2029 2030
- IMNM fair value vs current price
- IMNM insider transactions and insider buying
- Is IMNM undervalued or overvalued?
- Immunome Inc financial analysis — revenue, earnings, cash flow
- IMNM Piotroski F-Score and Altman Z-Score
- IMNM analyst price target and Smart Rating
Immunome Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Immunome Inc (IMNM) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Immunome Inc (IMNM) Key Strengths (2)
102.75% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Immunome Inc (IMNM) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 329.4x annual revenue
Premium pricing at 3.6x book value
Supporting Valuation Data
Immunome Inc (IMNM) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 8.5/10) while 5 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (329.41), Price/Book (3.60) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -52.10%, Operating Margin at -3085.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -52.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMNM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMNM's Price-to-Sales ratio of 329.41x sits near its historical average of 319.68x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 2% below its historical high of 334.46x set in Mar 2026, and 32% above its historical low of 249.19x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~249.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immunome Inc (IMNM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immunome Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 7M with 100% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 273M in cash.
Spending 731% of revenue (51M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -52M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.19, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immunome Inc.
Bottom Line
Immunome Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(3 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BIENAIME, JEAN JACQUES Director | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
BIENAIME, JEAN JACQUES Director | Buy | +1,000 |
| Insider | Type | Shares |
|---|---|---|
SIEGALL, CLAY B Director, President and CEO | Buy | +4,729 |
Data sourced from SEC Form 4 filings
Last updated: 12:57:01 PM
About Immunome Inc(IMNM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania.